Ketamine dosing continues to raise safety concerns.
Neuroimaging studies have shown several neurophysiological substrates for depression: An overview by Theodore Henderson, MD, PhD.
Byproduct of ketamine metabolism underlies the antidepressant-like activity of the agent in mice.
China's U.N. delegation has argued that ketamine is a health risk when it is used in a recreational fashion.
Ketamine and other drugs targeting the brain's NMDA receptors may benefit treatment-resistant depression.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Mood Stabilizers Associated With Increased Risk for Stroke in Bipolar Disorder
- Methylphenidate for ADHD Treatment May Be Associated With Low BMI
- Patients With Schizophrenia May Benefit From Occupational Therapy
- FDA Committees Vote on Opioid System Modulator for MDD Treatment
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Opioid Use Often Persists in Workers' Compensation Claimants
- Parental Mental Disorders Linked to Work Disabilities in Offspring
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- Mortality Rates in Parkinson Disease Psychosis With Pimavanserin, Quetiapine